Abstract library

12 results for "Hoffmann".
#36 A monocentric analysis of patients with pulmonary neuroendocrine tumors over 15 years: long term survival and life quality dependent from histological subtypes and surgical management
Introduction: Pulmonary neuroendocrine tumors substantially differ from epithelial tumors in terms of tumor biology and prognosis. In specialized interdisciplinary centers, a broad therapeutical armentarium can be used to achieve optimal treatment.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Johannes N Hoffmann
Authors: Zahn S, Hornung H, Schick K S, Winter H, ...
#326 Long-term Survival and Quality of Life in Patients with Ileum NET: A Single Center Experience
Introduction: Neuroendocrine tumors of the small bowel can be differentiated in terms of progression, survival time and health-related quality of life from endothelial tumors.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Anne Reincke
Authors: Reincke A, Zahn S, Hornung H, Jauch K W, ...
#327 Long-term Results and Life Quality in Patients with Pancreatic Neuroendocrine Tumors at Munich University-Großhadern
Introduction: PNETs substantially differ from epithelial tumors in terms of tumor biology and prognosis. In specialized centers, a broad interdiscipilary armentarium can be used to achieve optimal treatment.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Sabine Zahn
Authors: Zahn S, Reincke A, Hornung H, Jauch K W, ...
#363 Clinicopathological characteristics are capable of predicting long-term outcome of gastrointestinal neuroendocrine tumours in Germany
Introduction: Neuroendocrine tumours (NET) are a rare and heterogeneous group of neoplasm. Throughout the last decades the classification of NET has been both difficult and incoherent. Therefore making prognostic straticifation often difficult.
Conference:
Category: Basic
Presenting Author: Sebastian Maasberg
Keywords: outcome
#1237 Risk Factors for Survival from Neuroendocrine Neoplasia with Unknown Primary Tumor Site
Introduction: Neuroendocrine neoplasia (NEN) with unknown primary site (NEN-CUP) may have a poor prognosis. We evaluated the clinical presentation, therapy, outcome, and risk factors for adverse outcomes in patients with NEN-CUP.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: Dr. Nehara Begum
#1554 Combination of Lanreotide Autogel and Temozolomide in Patients with Progressive Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET) - A Pilot-Study
Introduction: Therapeutic options for patients with advanced progressive GEP-NET are still limited.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Prof. Dr. Markus Raderer
Authors: Raderer M, Hörsch D, Lahner H, Rinke A, ...
#1737 The Role of MAPK-Signalling in Pancreatic Neuroendocrine Cancer
Introduction: Upon diagnosis, 65% of pNET patients suffer from metastatic or locally unresectable disease. The receptor tyrosine kinase inhibitor sunitinib and the mTOR inhibitor everolimus have set precedence for successful targeted therapies in pNET disease. However, response prediction and treatment alternatives still do not meet medical needs. Recent studies revealed mutations in RAS oncogenes in a fraction of tumours, emphasising a potential role of the MAPK pathway as therapeutic target.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Julia Hoffmann
#1790 Lanreotide Autogel/Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study
Introduction: Treatment options for advanced lung NETs are limited. The phase 3 CLARINET study demonstrated antitumour efficacy of somatostatin analogue (SSA) LAN 120mg vs PBO for metastatic gastroenteropancreatic grade 1/2 (Ki-67<10%) NETs, but prospective data on SSAs in advanced lung NETs are lacking.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Diane Reidy-Lagunes
Keywords: Lung NETs, lanreotide
#1806 Epidemiology of Carcinoid Heart Disease (CHD) in Patients (pts) with Carcinoid Syndrome (CS): A Systematic Literature Review
Introduction: CHD develops in the context of CS due to the exposure of high levels of vasoactive substances, such as serotonin.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Olga Ovcinnikova
#1809 What Do We Know About Carcinoid Heart Disease? A Systematic Literature Review
Introduction: Carcinoid heart disease (CHD) is a life-threatening complication of carcinoid syndrome (CS).
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Olga Ovcinnikova